FKBP1A and tuberous sclerosis: mTOR inhibitors, namely rapamycin and everolimus, which act by forming a complex with FK506-binding protein-12 (FKBP12) that inhibits mTORC1, have shown clinical benefit in tuberous sclerosis patients (Jesus-Ribeiro et al., 2020).